Published in JAMA on June 24, 2009
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology (2015) 2.81
Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov (2016) 2.16
Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med (2010) 1.88
American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol (2014) 1.86
Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst (2013) 1.80
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst (2012) 1.74
Diabetes and pancreatic cancer. Mol Carcinog (2012) 1.71
Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut (2012) 1.66
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet (2011) 1.42
Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol (2012) 1.35
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control (2010) 1.29
Obesity adversely affects survival in pancreatic cancer patients. Cancer (2010) 1.28
Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog (2012) 1.26
Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr (2011) 1.26
A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer (2011) 1.25
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res (2010) 1.25
Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol (2012) 1.23
Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control (2010) 1.21
Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther (2010) 1.21
Screening for pancreatic cancer: why, how, and who? Ann Surg (2013) 1.19
Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol (2011) 1.18
Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology (2013) 1.18
Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.17
Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control (2012) 1.17
A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology (2013) 1.15
Mechanisms linking obesity and cancer. Biochim Biophys Acta (2013) 1.12
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer (2010) 1.10
Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol (2013) 1.08
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
Molecular biology of pancreatic cancer. World J Gastroenterol (2011) 1.02
Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr (2013) 1.01
A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res (2012) 0.99
Wellness: Pharmacy education's role and responsibility. Am J Pharm Educ (2010) 0.97
Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage (2012) 0.96
Coffee, tea, and sugar-sweetened carbonated soft drink intake and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Cancer Epidemiol Biomarkers Prev (2011) 0.96
Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol (2012) 0.94
Are risk factors associated with outcomes in pancreatic cancer? PLoS One (2012) 0.93
Association of diabetes and perineural invasion in pancreatic cancer. Cancer Med (2012) 0.93
Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol (2012) 0.93
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res (2016) 0.91
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS One (2015) 0.91
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer (2014) 0.89
Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am J Epidemiol (2013) 0.89
Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol (2015) 0.89
Obesity and survival in population-based patients with pancreatic cancer in the San Francisco Bay Area. Cancer Causes Control (2012) 0.88
Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol (2014) 0.88
Risk factors and therapeutic targets in pancreatic cancer. Front Oncol (2013) 0.88
Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer (2010) 0.88
Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. Int J Cancer (2011) 0.88
Obesity and survival among patients with pancreatic cancer. JAMA (2009) 0.85
Functional logistic regression approach to detecting gene by longitudinal environmental exposure interaction in a case-control study. Genet Epidemiol (2014) 0.84
Obesity and Cancer: An Angiogenic and Inflammatory Link. Microcirculation (2016) 0.84
Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat. Dig Dis Sci (2014) 0.83
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov (2015) 0.83
Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol (2016) 0.83
Current status and progress of pancreatic cancer in China. World J Gastroenterol (2015) 0.83
Increased Incidence of Second Primary Pancreatic Cancer in Patients with Prior Colorectal Cancer: A Population-Based US Study. Dig Dis Sci (2016) 0.82
The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol (2014) 0.82
Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract (2012) 0.82
Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. Am J Cancer Res (2015) 0.82
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One (2016) 0.82
Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol (2016) 0.82
Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer (2011) 0.81
Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila) (2011) 0.81
Chemoprevention of pancreatic cancer: ready for the clinic? Cancer Prev Res (Phila) (2010) 0.81
Effect of Body Mass Index on Overall Survival of Pancreatic Cancer: A Meta-Analysis. Medicine (Baltimore) (2016) 0.81
Early detection of pancreatic cancer. Chin J Cancer Res (2015) 0.80
Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea? Cardiovasc Diabetol (2014) 0.80
Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol (2015) 0.79
Obesity and Cancer: Concepts and Challenges. Indian J Surg Oncol (2015) 0.79
Premorbid Obesity and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol (2015) 0.79
Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida. BMC Cancer (2013) 0.79
Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver (2016) 0.78
Micronuclei levels in peripheral blood lymphocytes as a potential biomarker for pancreatic cancer risk. Carcinogenesis (2010) 0.78
Adipocytes enhance murine pancreatic cancer growth via a hepatocyte growth factor (HGF)-mediated mechanism. Int J Surg (2016) 0.78
Impact of body mass index on complications following pancreatectomy: Ten-year experience at National Cancer Center in China. World J Gastroenterol (2015) 0.77
Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol (2011) 0.77
Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am (2015) 0.77
Overweight, obesity, and pancreatic cancer: beyond risk alone. JAMA (2009) 0.77
Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res (2016) 0.77
ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med (2015) 0.77
Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy. J Cancer Res Clin Oncol (2014) 0.77
An Attempt to Evaluate Selected Aspects of "Bone-Fat Axis" Function in Healthy Individuals and Patients With Pancreatic Cancer. Medicine (Baltimore) (2015) 0.76
Energy balance and metabolism after cancer treatment. Semin Oncol (2013) 0.76
Evaluating the cause of death in obese individuals: a ten-year medical autopsy study. J Obes (2015) 0.76
Obesity as an important risk factor for certain types of cancer. Iran J Cancer Prev (2013) 0.76
Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences. Int J Clin Exp Med (2013) 0.76
Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas (2016) 0.76
Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol (2011) 0.76
Powerful Tukey's One Degree-of-Freedom Test for Detecting Gene-Gene and Gene-Environment Interactions. Cancer Inform (2015) 0.75
Diet and Pancreatic Cancer Prevention. Cancers (Basel) (2015) 0.75
Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. Cancers (Basel) (2011) 0.75
Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Pancreas (2016) 0.75
Overweight increases the risk of malignancy in patients with pancreatic mucinous cystic neoplasms. Medicine (Baltimore) (2015) 0.75
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 33.23
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA (2004) 25.36
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
Longitudinal changes in adiposity associated with pregnancy. The CARDIA Study. Coronary Artery Risk Development in Young Adults Study. JAMA (1994) 4.52
Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA (2001) 4.30
The accuracy of self-reported weights. Am J Clin Nutr (1981) 4.28
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology (2007) 3.60
Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. Am J Epidemiol (1990) 3.21
Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control (2006) 2.64
Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care (2001) 2.50
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Obesity and cancer risk among white and black United States veterans. Cancer Causes Control (2004) 2.36
Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer (2005) 2.33
Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer (2007) 2.22
Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev (2005) 2.16
Long-term memory of body weight and past weight satisfaction: a longitudinal follow-up study. Am J Clin Nutr (1991) 2.07
A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer (2003) 2.02
Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr (2006) 1.98
Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst (1998) 1.91
Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer (2005) 1.71
Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res (2008) 1.49
Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. Cancer Causes Control (2007) 1.42
Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol (2008) 1.35
Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev (2006) 1.32
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28
Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg (2009) 1.27
Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer (2007) 1.25
Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer (2001) 1.21
Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer (2004) 1.20
Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol (2007) 1.18
Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control (2005) 1.17
The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am J Epidemiol (2005) 1.06
The impact of obesity on surgical outcome after pancreaticoduodenectomy. JOP (2008) 0.99
Blood pressure in adolescence and early adulthood related to obesity and birth size. Obes Res (1998) 0.91
Obesity and pancreatic cancer: overall evidence and latency period. Cancer Epidemiol Biomarkers Prev (2005) 0.90
Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol (2006) 0.90
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 20.76
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Pancreatic cancer. Lancet (2004) 11.63
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell (2007) 7.05
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Methylation protects miRNAs and siRNAs from a 3'-end uridylation activity in Arabidopsis. Curr Biol (2005) 5.99
Dental x-rays and risk of meningioma. Cancer (2012) 5.99
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A (2009) 5.86
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science (2006) 5.52
The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30
Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med (2011) 5.11
Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res (2007) 4.99
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Electrochemical energy storage for green grid. Chem Rev (2011) 4.48
Towards a transgenic model of Huntington's disease in a non-human primate. Nature (2008) 4.47
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell (2012) 4.18
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke (2008) 3.81
Arabidopsis HEN1: a genetic link between endogenous miRNA controlling development and siRNA controlling transgene silencing and virus resistance. Curr Biol (2003) 3.77
Altitude and all-cause mortality in incident dialysis patients. JAMA (2009) 3.62
The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst (2005) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
HEN1 functions pleiotropically in Arabidopsis development and acts in C function in the flower. Development (2002) 3.24
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics (2003) 3.06
Cytogenetic effects in children treated with methylphenidate. Cancer Lett (2005) 3.05
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent. Am J Public Health (2005) 2.94
Tube Formation in Nanoscale Materials. Nanoscale Res Lett (2008) 2.83
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Complex and oriented ZnO nanostructures. Nat Mater (2003) 2.75
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol (2011) 2.61
Epidemiology of intracranial meningioma. Neurosurgery (2005) 2.60
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer (2011) 2.59
Age-related changes of nuclear architecture in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2005) 2.57
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology (2007) 2.53
Challenges in the development of high protein concentration formulations. J Pharm Sci (2004) 2.52
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Primary fascial closure with mesh reinforcement is superior to bridged mesh repair for abdominal wall reconstruction. J Am Coll Surg (2013) 2.42
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell (2010) 2.40
Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol (2005) 2.39
Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer (2004) 2.38
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene (2004) 2.35
Dynamics of Helicobacter pylori infection in a US-Mexico cohort during the first two years of life. Int J Epidemiol (2005) 2.33
NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog (2009) 2.32
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
Birthplace, years of residence in the United States, and obesity among Mexican-American adults. Obesity (Silver Spring) (2007) 2.28
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci U S A (2002) 2.24
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res (2003) 2.23
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumour Biol (2014) 2.14
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone. Plast Reconstr Surg (2012) 2.13
Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12
Reproducibility and validity of the secondary level School-Based Nutrition Monitoring student questionnaire. J Am Diet Assoc (2003) 2.11
Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res (2003) 2.11
HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol (2010) 2.10
The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic (2005) 2.08